Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
暂无分享,去创建一个
S. Jagannath | A. Jakubowiak | S. Lonial | R. Vij | P. Richardson | D. Reece | P. Moreau | T. Facon | J. Zonder | A. Singhal | D. White | M. Raab | L. Benboubker | E. Bleickardt | L. Tsao | K. Anderson